Coagulation factor VIII (activated) (FVIIIa)

Coagulation factor VIII (activated), commonly abbreviated as FVIIIa, is a critical glycoprotein cofactor in the intrinsic pathway of the coagulation cascade. Synthesized mainly by endothelial cells, FVIII is secreted into the bloodstream as an inactive procofactor, where it circulates bound to von Willebrand factor. Upon activation by thrombin, FVIII dissociates and undergoes cleavage to form FVIIIa, which consists of a heavy chain (A1-A2 domains) and a light chain (A3-C1-C2 domains) that assemble non-covalently. Activated FVIIIa binds to activated factor IX (FIXa) on phospholipid surfaces—principally platelets—forming the intrinsic tenase complex, which dramatically increases the rate of factor X activation to factor Xa, a pivotal event in thrombin generation and fibrin clot formation. Dysfunction or deficiency of FVIIIa results in hemophilia A, a severe bleeding disorder, while immune-mediated inhibition of FVIIIa (acquired hemophilia) is a rare but serious condition. Replacement therapy with FVIII or agents that mimic its action form the cornerstone of treatment, but therapeutic use is complicated by immunogenicity (formation of inhibitory antibodies) and, less commonly, by prothrombotic risks[1][2][3][4][7].

Other names

Factor VIIIaActivated coagulation factor VIIIAntihemophilic factor (activated)FVIIIa

Replacement therapy (provides functional FVIIIa to restore coagulation in deficient patients) Inhibition by monoclonal antibodies (inhibitors bind and neutralize FVIIIa activity) Mimicry/agonism (e.g., emicizumab bridges factor IXa and factor X to bypass the need for FVIIIa activity)